Since Stage I lung cancer patients as a group do not benefit from adjuvant therapy, and 40–50% are not cured with surgery alone, a biomarker such as the TGFβ-EMT signature that is predictive of relapse with the development of metastatic disease has the potential to identify patients who may possibly benefit from adjuvant therapy. Here, TGFB1 is linked to metastatic neoplasm.